Monitoring patients with rheumatoid arthritis in routine care: Experiences from a treat-to-target strategy using the DANBIO registry

Clinical and Experimental Rheumatology

Volumn 32, Issue , 2014, Pages S141-S146

  Hetland, Merete Lund ^a,d   Jensen, Dorte Vendelbo ^a,b   Krogh, Niels Steen ^c  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c Zitelab Aps   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

DANBIO registry; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; IMMUNOGLOBULIN M; METHOTREXATE; PREDNISOLONE; ANTIRHEUMATIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DENMARK; DESCRIPTIVE RESEARCH; DISABILITY; DISEASE ACTIVITY; DISEASE DURATION; FEASIBILITY STUDY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATIENT CARE; PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOLOGICAL PARAMETERS; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT PLANNING; ARTHRITIS, RHEUMATOID; CLINICAL PRACTICE; DISEASE COURSE; HEALTH CARE QUALITY; PRACTICE GUIDELINE; PREDICTIVE VALUE; REGISTER; SEVERITY OF ILLNESS INDEX; STANDARDS; TIME; TREATMENT OUTCOME;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DENMARK; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; REGISTRIES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; STANDARD OF CARE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84922393298     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. KLARESKOG L, CATRINA AI, PAGET S: Rheumatoid arthritis. Lancet 2009; 373: 659-72.
2. GLINTBORG B, OSTERGAARD M, DREYER L et al.: Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011; 63: 382-90.
3. HETLAND ML, LINDEGAARD HM, HANSEN A et al.: Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry. Ann Rheum Dis 2008; 67: 1023-6.
4. HETLAND ML, CHRISTENSEN IJ, TARP U et al.: Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010; 62: 22-32.
5. LEFFERS HC, OSTERGAARD M, GLINTBORG B et al.: Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 2011; 70: 1216-22.
6. LINDE L, SORENSEN J, ØSTERGAARD M, HORSLEV-PETERSEN K, HETLAND ML: Does clinical remission lead to normalization of EQ-5D in patients with rheumatoid arthritis and is selection of remission criteria important? J Rheumatol 2010; 37: 285-90.
7. LINDE L, SORENSEN J, OSTERGAARD M, HETLAND ML: Gain in quality-adjusted lifeyears in patients with rheumatoid arthritis during 1 year of biological therapy: a prospective study in clinical practice. J Rheumatol 2013; 40: 1479-86.
8. CHATZIDIONYSIOU K, LIE E, NASONOV E et al.: Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis 2012; 71: 374-7.
9. DREYER L, MELLEMKJAER L, ANDERSEN AR et al.: Incidences of overall and site specific cancers in TNFalpha inhibitor treated patients with rheumatoid arthritis and other arthritides-a follow-up study from the DANBIO Registry. Ann Rheum Dis 2013; 72: 79-82.
10. HETLAND ML, OSTERGAARD M, EJBJERG B et al.: Short-and long-term efficacy of intra-articular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis: impact of joint area, repeated injections, MRI findings, anti-CCP, IgM-RF and CRP. Ann Rheum Dis 2012; 71: 851-6.
11. JENSEN TW, HANSEN MS, HORSLEVPETERSEN K et al.: Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial. Ann Rheum Dis 2014; 73: 1123-9.
12. HORSLEV-PETERSEN K, HETLAND ML, JUNKER P et al.: Adalimumab added to a treat-totarget strategy with methotrexate and intraarticular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, doubleblind, parallel-group, placebo-controlled trial. Ann Rheum Dis 2014; 73: 654-61.
13. HETLAND ML, HORSLEV-PETERSEN K: The CIMESTRA study: intra-articular glucocorticosteroids and synthetic DMARDs in a treat-to-target strategy in early rheumatoid arhtritis. Clin Exp Rheumatol 2012; 30 (Suppl. 73): S44-S49.
14. SMOLEN JS, LANDEWé R, BREEDVELD FC et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492-509.
15. HETLAND ML: DANBIO-powerful research database and electronic patient record. Rheumatology (Oxford) 2011; 50: 69-77.
16. SCHEFTE DB, HETLAND ML: An open-source, self-explanatory touch screen in routine care. Validity of filling in the Bath measures on Ankylosing Spondylitis Disease Activity Index, Function Index, the Health Assessment Questionnaire and Visual Analogue Scales in comparison with paper versions. Rheumatology (Oxford) 2010; 49: 99-104.
17. GLINTBORG B, OSTERGAARD M, KROGH NS et al.: Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor alpha inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum 2013; 65: 1213-23.
18. GLINTBORG B, OSTERGAARD M, KROGH NS et al.: Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor alpha inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 2013; 72: 1149-55.
19. KRINTEL SB, PALERMO G, JOHANSEN JS et al.: Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFalpha inhibitors in patients with rheumatoid arthritis. Pharmacogenet Genomics 2012; 22: 577-89.
20. PEDERSEN M, KLARLUND M, JACOBSEN S, SVENDSEN AJ, FRISCH M: Validity of rheumatoid arthritis diagnoses in the Danish National Patient Registry. Eur J Epidemiol 2004; 19: 1097-103.
21. SUNDHEDSSTYRELSEN CFEOMT: Leddegigt-medicinsk teknologivurdering af diagnostik og behandling. Medicinsk Teknologivurdering 2002.
22. Sundhed og sygelighed i Danmark 2000 & udviklingen siden 1987. Statens Institut for Folkesundhed; 2002.
23. KJØLLER M, RASMUSSEN NK, KEIDING L, PETERSEN HC, NIELSEN GA: Sundhed og sygelighed i Danmark 1994-og udviklingen siden 1987. En rapport fra DIKEs repræsentative undersøgelse blandt voksne danskere. København, DIKE; 1995.
24. KVIEN TK, GLENNAS A, KNUDSROD OG, SMEDSTAD LM, MOWINCKEL P, FORRE O: The prevalence and severity of rheumatoid arthritis in Oslo. Results from a county register and a population survey. Scand J Rheumatol 1997; 26: 412-8.
25. JENSEN DV, HETLAND ML: DANBIO Årsrapport 2013. 2014.
26. NISHIMURA K, SUGIYAMA D, KOGATA Y et al.: Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146: 797-808.